Discover
DMAC
DiaMedica Therapeutics Inc.
7.44
2 x 5.34
2 x 8.98
bid
ask
+
0.40
5.68%
2 @ 04:00 PM
7.88 +0.44 (5.89%)
| Ytd | -6.53% | |
| 1y | 108.40% |
6.98
day range
7.49
3.48
52 week range
10.42
| Open | 7.02 | Prev Close | 7.04 | Low | 6.98 | High | 7.49 | Mkt Cap | 400.89M |
| Vol | 275.99K | Avg Vol | 192.81K | EPS | -0.71 | P/E | N/A | Forward P/E | -7.26 |
| Beta | 1.46 | Short Ratio | 3.88 | Inst. Own | 31.61% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-06 | 50-d Avg | 6.09 | 200-d Avg | 7.17 | 1yr Est | 7.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-13 | 2024-09 | -0.15 | -0.15 | N/A | N/A |
| 2024-08-07 | 2024-06 | -0.16 | -0.13 | 0.03 | 18.75% |
| 2024-08-07 | 2024-06 | -0.16 | N/A | N/A | N/A |
| 2024-05-08 | 2024-03 | -0.16 | -0.14 | 0.02 | 12.50% |
| 2024-05-08 | 2024-03 | -0.16 | N/A | N/A | N/A |
| 2024-03-19 | 2023-12 | -0.14 | -0.14 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-07 | HC Wainwright & Co. | Upgrade | Buy | |
| 2024-08-16 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2024-03-21 | Craig-Hallum | Upgrade | Buy | Buy |
| 2024-03-21 | Oppenheimer | Upgrade | Outperform | Outperform |
Profile
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-01-01 | GIUFFRE RANDALL MICHAEL | Director | 411.19K | Stock Award(Grant) |
| 2023-06-22 | KELLEN SCOTT | Chief Financial Officer | 32.29K | Purchase |
| 2024-01-01 | KUNTZ RICHARD P | Director | 14.29K | Stock Award(Grant) |
| 2024-01-01 | PARSONS JAMES T CPA | Director | 59.94K | Stock Award(Grant) |
| 2023-06-22 | PAULS DIETRICH JOHN | Chief Executive Officer | 68.59K | Purchase |
| 2024-01-01 | PILNIK RICHARD D | Director | 278.60K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Cooperman, Leon G. | 1.51M | 8.13M | 3.54% |
| 2024-09-29 | Vanguard Group Inc | 1.05M | 5.64M | 2.45% |
| 2024-09-29 | First Manhattan Co. LLC | 839.08K | 4.51M | 1.96% |
| 2024-09-29 | Paragon Associates & Paragon Associates Ii Joint Venture | 482.61K | 2.59M | 1.13% |
| 2024-09-29 | Bleichroeder LP | 382.32K | 2.05M | 0.89% |
| 2024-09-29 | Geode Capital Management, LLC | 306.96K | 1.65M | 0.72% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 747.20K | 4.02M | 1.75% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 253.73K | 1.36M | 0.59% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 149.06K | 801.18K | 0.35% |
| 2024-10-30 | Jacob Discovery Fd | 114.73K | 616.67K | 0.27% |
| 2024-10-30 | iShares Micro Cap ETF | 55.12K | 296.25K | 0.13% |
| 2024-10-30 | Fidelity Total Market Index Fund | 48.73K | 261.95K | 0.11% |
Split
| Split | Date |
|---|---|
| 1 : 20 | 2018-11-15 |